Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEPtalk 2 pilot trial of VZIG versus aciclovir after varicella exposure in children with cancer
2013-001332-22Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- May 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in chickenpox comparing VZIG with Aciclovir (2 arms). Primary endpoint: Recruitment rate within 12 months. Started May 2013; status: completed.
02
Drugs
human varicella-zoster immune globulinaciclovir
03
Conditions
chickenpox
Beyond the preview
Go deeper on 2013-001332-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001332-22.